Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 6268Carcinoma, Renal Cell 1913Urinary Bladder Neoplasms 1670Kidney Neoplasms 930Breast Neoplasms 793Neoplasms 788Carcinoma, Transitional Cell 592Carcinoma, Non-Small-Cell Lung 524Neoplasm Metastasis 510Melanoma 484Ovarian Neoplasms 468Colorectal Neoplasms 454Lung Neoplasms 435Pancreatic Neoplasms 325Testicular Neoplasms 290Stomach Neoplasms 274Sarcoma 266Uterine Cervical Neoplasms 264Non-Muscle Invasive Bladder Neoplasms 263Head and Neck Neoplasms 241Colonic Neoplasms 217Esophageal Neoplasms 203Squamous Cell Carcinoma of Head and Neck 202Carcinoma, Hepatocellular 197Wilms Tumor 196Endometrial Neoplasms 189Recurrence 162Neuroblastoma 148Urologic Neoplasms 147Small Cell Lung Carcinoma 146

Interventions

luprolide acetate gel depot 1enzalutamide 1Triptorelin Pamoate 1Radiosurgery 1Leuprolide 1Goserelin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Castration-resistant Prostate Cancer Patients with Oligometastases × Genitourinary × Clear all
NCT02685397 2024-12-04

PCS IX

Sir Mortimer B. Davis - Jewish General Hospital

Phase 2/3 Active not recruiting
102 enrolled
Genitourinary

Castration-resistant Prostate Cancer Patients with Oligometastases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡